SPRY ARS Pharmaceuticals Inc

$SPRY with such poor sales and poor management, they’re going to have to raise capital soon.

$SPRY New management will be likely be seeking a near term win to prove they were the right choice/decision. They will still blame previous management for Q3 numbers if they are poor and will take credit for any positive forward guidance. Do I like the stock? No. I don't like the company and I hate it long term. But for a short term pop, I like it. Lot of eyes on it, sitting on the fence. Solid history of FOMO buying on news. It's primed for something to happen between now and November ER. Right after that is the ACAAI meeting. The biggest commercial event of the year for them. They will want to walk in there for the first time with a solid ER and news worthy victory to brag about. Then it will probably have a CVS formulary run in December. Volume is piss poor. Its oversold. Short availability is high. Borrow fees are so-so, in the 2's, but somewhat steady. My buy zone is anything sub $4.50. Won't touch it above that.

$SPRY how is your pumping working you? why not do more spamming? perhaps someone as supid as you and bean will invest in this POS. And don't forget to like your posts.

$SPRY $AQST Once it is completed, the rest of competitors in epi space are done, can close their shop and go home

$SPRY Lots of nasal spray competition coming neffy's way. Anaphylm™ Aquestive Therapeutics Sublingual film NDA received FDA Complete Response Letter Jan. 2026; Q3 2026 resubmission planned Hikma Hikma Pharmaceuticals Liquid nasal spray NDA accepted by FDA for review Sept. 2026 NS002 Nasus Pharma Dry-powder nasal Phase 2 completed; pivotal study planned Q4 2026 Nasdepi® Belhaven Biopharma Dry-powder nasal IND accepted; pivotal biocomparability study planned OX640 Orexo Dry-powder nasal Two clinical studies completed; advancing toward pivotal development; seeking partner IN-001 Insignis Therapeutics Sublingual liquid via prefilled oral syringe Phase 1 completed; Phase 2 in preparation ZENEO® Crossject Needle-free transcutaneous IM injection Clinical/device development ongoing; 2028 target timeframe

$SPRY cash flow to break even in 2027. #undervaluedasset #epinephrine #marketexpansion $MRK $SNY Great print. 7.34k TRX. 6% market share. Looks like early refills starting to kick in. NRX 5.7k. 5.3% market share.

$SPRY Sleeper pipeline. Cutting cash-based SG&A by 40%+ while expanding the pipeline. CSU/chronic hives Phase 2b data expected Q1 2027 - a potential multibillion-dollar market. ARS-1 has also been studied in Phase 2 for persistent asthma versus albuterol. Cut costs. Expand indications. Add potential market value. $AXSM

$SPRY Just posting information. ARS did everything possible to block anaphylm from approval. Carry rates are an issue with epinephrine delivery. People lose their lives to anaphalaxis because they fail to carry to proper life saving device. Anaphylm can have a material impact on carry rates as a credit card sized pouch can easily fit on the back of a phone or in a wallet. This is a particular problems with young adults. In addition, time to Tmax is much faster with anaphylm. Despite the fact that lives could be saved, ARS still tried to block this from getting to patients. I do not wish ARS well. They only care about the bottom line (like most TBH). I hope Anaphylm is approved and eats their lunch. Biotech is cutthroat, and I hope Anaphylm wins. Non-device and faster time to tmax is a game changer. You know this. Understand this risk if you decide to hold SPRY long term. GL

$SPRY great print. 7.34k TRX. 6% market share. Looks like early refills starting to kick in. NRX 5.7k. 5.3% market share.

$SPRY hey big T ..you know SPRY and AQST short interest are virtually identical right? Only reason why you’re seeing 38 percent SI on SPRY is because the top 4 holders (some of the most prestigious healthcare funds in world) are long conviction holds and don’t day trade. They hold a ton of shares and bring the float to 63mil shares instead of 100mil… AQST 21 percent short outstanding shares Spry 23 percent SPRY massively bigger short squeeze potential due to the smaller float as stated above Food for thought buddy thought I’d educate you 😉

$SPRY Not a fan of SPRY, for multiple reasons, but mid $4's sub $4's, it does become attractive. Their one product didn't fail, former management failed the launch. Add to that, the obvious behind the scenes battle with Viatris has also slowed the launch. Before, after approval, the market gifted SPRY with a valuation that indicated a fast, successful launch. SPRY failed at that. Now, with new management, the market is now in 'prove it' mode. Giving SPRY a low valuation until they show they can launch Neffy they way it should. The market will want, likely, 2 quarters worth of time to see if new management can do the job, The CVS formulary approval, IF APPROVED, come January 2027, will be a big boost. This a good play to play, to run up into 3rdQ ER and the CVS formulary. The better play will always be AQST. But SPRY might have some bigger pops before AQST makes its 1X, 2X, 3X move. I wouldn't touch SPRY over $4.50. But under it, I would flip in and out of it for sure.

$SPRY No one cares about CVS... This company will run out of money anyway... Possible pump into CVS but they will do an offering...

$SPRY countdown is on. Less than 30 days until earnings and cvs decision…exciting times to come!

$SPRY made real good money here when fda denied it dirst round now loading again hee for a good pop

$SPRY Fact. No matter what you think of this play and its glaring, massive failures , it's still going to pop huge on the CVS formulary approval coming up.

$SPRY has NEW leadership with significant commercialization experience. CEO Donn Casale spent 14 years at $MRK later became CCO of Dynavax, helping drive HEPLISAV-B’s commercial growth. Dynavax was ultimately acquired by $SNY / Sanofi for approximately $ 2.2B. The story is simple. neffy is the first FDA and globally approved epinephrine nasal spray for severe allergic reactions-a needle-free alternative to traditional auto-injectors. It launched LESS THAN 2 years ago and is already in 13,000+ schools.

$SPRY Market continues to reward fantastic execution and performance of this miracle drug.

$SPRY $AXSM, $MIRM, $TARS and $ADMA are good reminders that biotech commercialization takes time - and successful launches can create significant value once adoption gains traction. That’s why I’m watching $SPRY closely. neffy’s Q2 2026 numbers show real commercial momentum: • $26.2M U.S. product revenue, +105% YoY • $33.7M total revenue, +114% YoY • U.S. epinephrine share 2.5% → 5% • Targeted-account share 4% → 8% • 16,000+ prescribers, nearly 3x YoY And now NEW management is attacking the other side of the equation: cash-based SG&A is expected to decline >40% in H2 vs. H1, with cash-flow breakeven targeted by YE 2027. Plus CSU Phase 2b interim data expected Q1 2027, potentially expanding the same intranasal epinephrine platform into another indication. My $SPRY thesis is simple: adoption is growing, market share is growing, prescribers are growing-and spending is being cut. Now execution has to follow. $SPRY $AXSM $MIRM $TARS $ADMA

$SPRY $AQST read the fine print: NO head-to-head comparison studies have been conducted with Anaphylm and Neffy. Aquestive Therapeutics, Inc. data results on file, excluding T-max data results for Neffy, which can be found in the prescribing information located in the approved product label

$SPRY $AQST peak absorption time matters. nasal spray may get you there in 30min if you don't leave it at home. ALso think about why many stayed with epipen. .... absorbtion time for sure has something to do with it.